CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?
Barbui
Corrado
C
Section of Psychiatry and Clinical Psychology, University of Verona, Policlinico GB Rossi, Piazzale Scuro 10, 37134, Verona, Italy. corrado.barbui@univr.it
Cipriani
Andrea
A
Lintas
Camilla
C
Bertelé
Vittorio
V
Garattini
Silvio
S
D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D004059:Diffusion of Innovation; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D005060:Europe; D005062:European Union; D006801:Humans; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D011785:Quality Assurance, Health Care / Q000331:legislation & jurisprudence; D016896:Treatment Outcome
D011619:Psychotropic Drugs